In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.
Download this PDF resource of expert recommendations on the optimal use of immune checkpoint inhibitors in patients with advanced NSCLC, including therapy selection and adverse event management.
In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.
Expert faculty from the 2017-2018 CCO Local Live meeting series “Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC” answer frequently asked questions about treating squamous NSCLC, including considerations regarding tumor mutational burden, optimal sequencing of therapy, and future directions.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.